Pediatric Cardiomyopathies: Causes, Epidemiology, Clinical Course, Preventive Strategies and Therapies

Overview

Journal Future Cardiol

Specialty Cardiology & Vascular Diseases

Date 2013 Nov 5

PMID 24180540

Citations 44

Authors

Steven E Lipshultz

Thomas R Cochran

David A Briston

Stefanie R Brown

Peter J Sambatakos

Tracie L Miller

Adriana A Carrillo

Liat Corcia

Janine E Sanchez

Melissa B Diamond

Michael Freundlich

Danielle Harake

Tamara Gayle

William G Harmon

Paolo G Rusconi

Satinder K Sandhu

James D Wilkinson

Affiliations

Soon will be listed here.

Abstract

Pediatric cardiomyopathies, which are rare but serious disorders of the muscles of the heart, affect at least one in every 100,000 children in the USA. Approximately 40% of children with symptomatic cardiomyopathy undergo heart transplantation or die from cardiac complications within 2 years. However, a significant number of children suffering from cardiomyopathy are surviving into adulthood, making it an important chronic illness for both pediatric and adult clinicians to understand. The natural history, risk factors, prevalence and incidence of this pediatric condition were not fully understood before the 1990s. Questions regarding optimal diagnostic, prognostic and treatment methods remain. Children require long-term follow-up into adulthood in order to identify the factors associated with best clinical practice including diagnostic approaches, as well as optimal treatment approaches. In this article, we comprehensively review current research on various presentations of this disease, along with current knowledge about their causes, treatments and clinical outcomes.

Citing Articles

Alternative Splicing in the Heart: The Therapeutic Potential of Regulating the Regulators.

Briganti F, Wang Z Int J Mol Sci. 2024; 25(23.

PMID: 39684734 PMC: 11641712. DOI: 10.3390/ijms252313023.

Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis.

Malinow I, Fong D, Miyamoto M, Badran S, Hong C Front Pediatr. 2024; 12:1404942.

PMID: 38966492 PMC: 11223501. DOI: 10.3389/fped.2024.1404942.

Unraveling the genetic tapestry of pediatric sarcomeric cardiomyopathies and masquerading phenocopies in Jordan.

Azab B, Aburizeg D, Shaaban S, Ji W, Mustafa L, Isbeih N Sci Rep. 2024; 14(1):15141.

PMID: 38956129 PMC: 11219879. DOI: 10.1038/s41598-024-64921-9.

Familial dilated cardiomyopathy in a child: a case report.

Ismail A, Khreis D, Assaad A, Majdalani M BMC Pediatr. 2024; 24(1):226.

PMID: 38561731 PMC: 10983683. DOI: 10.1186/s12887-024-04614-4.

Administrative Databases: Friend or Foe in Paediatric Cardiomyopathy.

Conway J, Barrett O, Pidborochynski T, Schroeder K, Cunningham C, Jeewa A CJC Pediatr Congenit Heart Dis. 2024; 2(6Part B):490-493.

PMID: 38205436 PMC: 10777199. DOI: 10.1016/j.cjcpc.2023.09.009.

References

Foerster S, Canter C, Cinar A, Sleeper L, Webber S, Pahl E . Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail. 2010; 3(6):689-97. DOI: 10.1161/CIRCHEARTFAILURE.109.902833. View

Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T . Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78(10):975-80. DOI: 10.1038/ki.2010.313. View

Denfield S, Rosenthal G, Gajarski R, Bricker J, Schowengerdt K, Price J . Restrictive cardiomyopathies in childhood. Etiologies and natural history. Tex Heart Inst J. 1997; 24(1):38-44. PMC: 325396. View

Driscoll D, Edwards W . Sudden unexpected death in children and adolescents. J Am Coll Cardiol. 1985; 5(6 Suppl):118B-121B. DOI: 10.1016/s0735-1097(85)80540-4. View

Verma S, Khadwal A, Chopra K, Rohit M, Singhi S . Hypocalcemia nutritional rickets: a curable cause of dilated cardiomyopathy. J Trop Pediatr. 2010; 57(2):126-8. DOI: 10.1093/tropej/fmq044. View

Tsai S, Ebenroth E, Hurwitz R, Cordes T, Schamberger M, Batra A . Is left ventricular noncompaction in children truly an isolated lesion?. Pediatr Cardiol. 2009; 30(5):597-602. DOI: 10.1007/s00246-008-9382-1. View

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

Tyralla K, Adamczak M, Benz K, Campean V, Gross M, Hilgers K . High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS One. 2011; 6(1):e15287. PMC: 3029304. DOI: 10.1371/journal.pone.0015287. View

Lipshultz S, Vlach S, Lipsitz S, Sallan S, Schwartz M, Colan S . Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics. 2005; 115(6):1613-22. DOI: 10.1542/peds.2004-1004. View

10.

Rodday A, Triedman J, Alexander M, Cohen J, Ip S, Newburger J . Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics. 2012; 129(4):e999-1010. PMC: 3313631. DOI: 10.1542/peds.2011-0643. View

11.

Xiang W, Kong J, Chen S, Cao L, Qiao G, Zheng W . Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2004; 288(1):E125-32. DOI: 10.1152/ajpendo.00224.2004. View

12.

Silva C, Bacal F, Benvenuti L, Bocchi E . Desmin-related restrictive cardiomyopathy. Arq Bras Cardiol. 2008; 89(6):165-8. View

13.

Unger R . Lipotoxic diseases. Annu Rev Med. 2002; 53:319-36. DOI: 10.1146/annurev.med.53.082901.104057. View

14.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

15.

Murphy R, Thaman R, Blanes J, Ward D, Sevdalis E, Papra E . Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J. 2004; 26(2):187-92. DOI: 10.1093/eurheartj/ehi025. View

16.

Gruppen M, Groothoff J, Prins M, van der Wouw P, Offringa M, Bos W . Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int. 2003; 63(3):1058-65. DOI: 10.1046/j.1523-1755.2003.00814.x. View

17.

Ostman-Smith I, Wettrell G, Riesenfeld T . A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999; 34(6):1813-22. DOI: 10.1016/s0735-1097(99)00421-0. View

18.

Pilz S, Iodice S, Zittermann A, Grant W, Gandini S . Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011; 58(3):374-82. DOI: 10.1053/j.ajkd.2011.03.020. View

19.

Gersh B, Maron B, Bonow R, Dearani J, Fifer M, Link M . 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124(24):2761-96. DOI: 10.1161/CIR.0b013e318223e230. View

20.

Hsu H, Wu M . Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337(2):116-22. DOI: 10.1097/MAJ.0b013e3181815498. View